| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals, Inc.
13D/A
Amendment 12
PHAT · 71722W107
|
7.4% |
11/2/2026
Event 10/29/2026
|
|||
| Frazier Life Sciences Public Fund, L.P. | 6.5% | ||||
| FHMLSP, L.P. | 6.5% | ||||
| FHMLSP, L.L.C. | 6.5% | ||||
| Frazier Life Sciences X, L.P. | 0.1% | ||||
| FHMLS X, L.P. | 0.1% | ||||
| FHMLS X, L.L.C. | 0.1% | ||||
| Frazier Life Sciences XI, L.P. | 1.2% | ||||
| FHMLS XI, L.P. | 1.2% | ||||
| FHMLS XI, L.L.C. | 1.2% | ||||
| Frazier Life Sciences IX, L.P. | 7.2% | ||||
| FHMLS IX, L.P. | 7.2% | ||||
| FHMLS IX, L.L.C. | 7.2% | ||||
| Frazier Life Sciences XII, L.P. | 0.3% | ||||
| FHMLS XII, L.P. | 0.3% | ||||
| FHMLS XII, L.L.C. | 0.3% | ||||
| James N. Topper | 7.4% | ||||
| Patrick J. Heron | 7.3% | ||||
|
Q32 Bio Inc.
13G
QTTB · 746964105
|
5.9% |
10/9/2026
Event 10/2/2026
|
|||
| Frazier Life Sciences Public Fund, L.P. | 5.9% | ||||
| FHMLSP, L.P. | 5.9% | ||||
| FHMLSP, L.L.C. | 5.9% | ||||
| Frazier Life Sciences XI, L.P. | 0.1% | ||||
| FHMLS XI, L.P. | 0.1% | ||||
| FHMLS XI, L.L.C. | 0.1% | ||||
| Frazier Life Sciences XII, L.P. | 0.4% | ||||
| FHMLS XII, L.P. | 0.4% | ||||
| FHMLS XII, L.L.C. | 0.4% | ||||
|
Aclaris Therapeutics, Inc.
13G
ACRS · 00461U105
|
5.4% |
9/21/2026
Event 9/14/2026
|
|||
| Frazier Life Sciences Public Fund, L.P. | 5.4% | ||||
| FHMLSP, L.P. | 5.4% | ||||
| FHMLSP, L.L.C. | 5.4% | ||||
| Frazier Life Sciences XI, L.P. | 0.1% | ||||
| FHMLS XI, L.P. | 0.1% | ||||
| FHMLS XI, L.L.C. | 0.1% | ||||
| Frazier Life Sciences XII, L.P. | 0.5% | ||||
| FHMLS XII, L.P. | 0.5% | ||||
| FHMLS XII, L.L.C. | 0.5% | ||||
|
Aura Biosciences, Inc.
13G/A
Amendment 3
AURA · 05153U107
|
5.6% |
8/14/2026
Event 6/30/2026
|
|||
| Frazier Life Sciences Public Fund, L.P. | 5.6% | ||||
| FHMLSP, L.P. | 5.6% | ||||
| FHMLSP, L.L.C. | 5.6% | ||||
| Frazier Life Sciences X, L.P. | 0.1% | ||||
| FHMLS X, L.P. | 0.1% | ||||
| FHMLS X, L.L.C. | 0.1% | ||||
| Frazier Life Sciences XI, L.P. | 0.3% | ||||
| FHMLS XI, L.P. | 0.3% | ||||
| FHMLS XI, L.L.C. | 0.3% | ||||
| Frazier Life Sciences XII, L.P. | 0.8% | ||||
| FHMLS XII, L.P. | 0.8% | ||||
| FHMLS XII, L.L.C. | 0.8% | ||||
| James N. Topper | 0.1% | ||||
| Patrick J. Heron | 0.1% | ||||
|
Allogene Therapeutics, Inc.
13G/A
Amendment 1
ALLO · 019770106
|
5.6% |
8/14/2026
Event 6/30/2026
|
|||
| Frazier Life Sciences Public Fund, L.P. | 5.6% | ||||
| FHMLSP, L.P. | 5.6% | ||||
| FHMLSP, L.L.C. | 5.6% | ||||
| Frazier Life Sciences X, L.P. | 0.1% | ||||
| FHMLS X, L.P. | 0.1% | ||||
| FHMLS X, L.L.C. | 0.1% | ||||
| Frazier Life Sciences XI, L.P. | 0.2% | ||||
| FHMLS XI, L.P. | 0.2% | ||||
| FHMLS XI, L.L.C. | 0.2% | ||||
| Frazier Life Sciences XII, L.P. | 0.6% | ||||
| FHMLS XII, L.P. | 0.6% | ||||
| FHMLS XII, L.L.C. | 0.6% | ||||
| James N. Topper | 0.1% | ||||
| Patrick J. Heron | 0.1% | ||||
|
Vor Biopharma Inc.
13G/A
Amendment 1
VOR · 929033207
|
4.2% |
8/14/2026
Event 6/30/2026
|
|||
| Frazier Life Sciences Public Fund, L.P. | 4.2% | ||||
| FHMLSP, L.P. | 4.2% | ||||
| FHMLSP, L.L.C. | 4.2% | ||||
| Frazier Life Sciences XI, L.P. | 0% | ||||
| FHMLS XI, L.P. | 0% | ||||
| FHMLS XI, L.L.C. | 0% | ||||
| Frazier Life Sciences XII, L.P. | 0.5% | ||||
| FHMLS XII, L.P. | 0.5% | ||||
| FHMLS XII, L.L.C. | 0.5% | ||||
|
Braveheart Bio, Inc.
13G
BRVE · 10567X101
|
5.5% |
8/14/2026
Event 8/7/2026
|
|||
| Frazier Life Sciences Public Fund, L.P. | 5.5% | ||||
| FHMLSP, L.P. | 5.5% | ||||
| FHMLSP, L.L.C. | 5.5% | ||||
| Frazier Life Sciences XI, L.P. | 0% | ||||
| FHMLS XI, L.P. | 0% | ||||
| FHMLS XI, L.L.C. | 0% | ||||
| Frazier Life Sciences XII, L.P. | 0.1% | ||||
| FHMLS XII, L.P. | 0.1% | ||||
| FHMLS XII, L.L.C. | 0.1% | ||||
|
Attovia Therapeutics, Inc.
13D
ATTO · 04987L102
|
13.5% |
8/11/2026
Event 8/6/2026
|
|||
| Frazier Life Sciences Public Fund, L.P. | 1.7% | ||||
| FHMLSP, L.P. | 1.7% | ||||
| FHMLSP, L.L.C. | 1.7% | ||||
| Frazier Life Sciences XI, L.P. | 13.5% | ||||
| FHMLS XI, L.P. | 13.5% | ||||
| FHMLS XI, L.L.C. | 13.5% | ||||
| Frazier Life Sciences XII, L.P. | 0.1% | ||||
| FHMLS XII, L.P. | 0.1% | ||||
| FHMLS XII, L.L.C. | 0.1% | ||||
|
MBX Biosciences, Inc.
13D/A
Amendment 3
MBX · 55287L101
|
11.7% |
8/10/2026
Event 8/6/2026
|
|||
| Frazier Life Sciences Public Fund, L.P. | 3.0% | ||||
| FHMLSP, L.P. | 3.0% | ||||
| FHMLSP, L.L.C. | 3.0% | ||||
| Frazier Life Sciences X, L.P. | 10.8% | ||||
| FHMLS X, L.P. | 10.8% | ||||
| FHMLS X, L.L.C. | 10.8% | ||||
| Frazier Life Sciences XI, L.P. | 0% | ||||
| FHMLS XI, L.P. | 0% | ||||
| FHMLS XI, L.L.C. | 0% | ||||
| James N. Topper | 11.7% | ||||
| Patrick J. Heron | 11.7% | ||||
|
KalVista Pharmaceuticals, Inc.
13D/A
Amendment 8
KALV · 483497103
|
2.3% |
5/21/2026
Event 5/19/2026
|
|||
| Frazier Life Sciences Public Fund, L.P. | 2.3% | ||||
| FHMLSP, L.P. | 2.3% | ||||
| FHMLSP, L.L.C. | 2.3% | ||||
| Frazier Life Sciences X, L.P. | 0.8% | ||||
| FHMLS X, L.P. | 0.8% | ||||
| FHMLS X, L.L.C. | 0.8% | ||||
| Frazier Life Sciences XI, L.P. | 0.3% | ||||
| FHMLS XI, L.P. | 0.3% | ||||
| FHMLS XI, L.L.C. | 0.8% | ||||
| Frazier Life Sciences XII, L.P. | 0% | ||||
| FHMLS XII, L.P. | 0% | ||||
| FHMLS XII, L.L.C. | 0% | ||||
| James N. Topper | 0.8% | ||||
| Patrick J. Heron | 0.8% | ||||
|
Valneva SE
13G
VALN · 92025Y103
|
3.6% |
5/12/2026
Event 5/5/2026
|
|||
| Frazier Life Sciences Public Fund, L.P. | 3.6% | ||||
| FHMLSP, L.P. | 3.6% | ||||
| FHMLSP, L.L.C. | 3.6% | ||||
| Frazier Life Sciences X, L.P. | 0.1% | ||||
| FHMLS X, L.P. | 0.1% | ||||
| FHMLS X, L.L.C. | 0.1% | ||||
| Frazier Life Sciences XI, L.P. | 0.2% | ||||
| FHMLS XI, L.P. | 0.2% | ||||
| FHMLS XI, L.L.C. | 0.2% | ||||
| Frazier Life Sciences XII, L.P. | 0.5% | ||||
| FHMLS XII, L.P. | 0.5% | ||||
| FHMLS XII, L.L.C. | 0.5% | ||||
| James N. Topper | 0.1% | ||||
| Patrick J. Heron | 0.1% | ||||
|
iBio, Inc.
13G/A
Amendment 1
IBIO · 451033708
|
5.7% |
5/12/2026
Event 3/31/2026
|
|||
| Frazier Life Sciences Public Fund, L.P. | 5.7% | ||||
| FHMLSP, L.P. | 5.7% | ||||
| FHMLSP, L.L.C. | 5.7% | ||||
| Frazier Life Sciences XI, L.P. | 0% | ||||
| FHMLS XI, L.P. | 0% | ||||
| FHMLS XI, L.L.C. | 0% | ||||
| Frazier Life Sciences XII, L.P. | 0% | ||||
| FHMLS XII, L.P. | 0% | ||||
| FHMLS XII, L.L.C. | 0% | ||||
|
Achieve Life Sciences, Inc.
13G
ACHV · 004468500
|
6.5% |
4/24/2026
Event 4/17/2026
|
|||
| Frazier Life Sciences Public Fund, L.P. | 6.5% | ||||
| FHMLSP, L.P. | 6.5% | ||||
| FHMLSP, L.L.C. | 6.5% | ||||
| Frazier Life Sciences XI, L.P. | 0.1% | ||||
| FHMLS XI, L.P. | 0.1% | ||||
| FHMLS XI, L.L.C. | 0.1% | ||||
| Frazier Life Sciences XII, L.P. | 0.8% | ||||
| FHMLS XII, L.P. | 0.8% | ||||
| FHMLS XII, L.L.C. | 0.8% | ||||
|
Allogene Therapeutics, Inc.
13G
ALLO · 019770106
|
4.7% |
4/23/2026
Event 4/16/2026
|
|||
| Frazier Life Sciences Public Fund, L.P. | 4.7% | ||||
| FHMLSP, L.P. | 4.7% | ||||
| FHMLSP, L.L.C. | 4.7% | ||||
| Frazier Life Sciences X, L.P. | 0.1% | ||||
| FHMLS X, L.P. | 0.1% | ||||
| FHMLS X, L.L.C. | 0.1% | ||||
| Frazier Life Sciences XI, L.P. | 0.2% | ||||
| FHMLS XI, L.P. | 0.2% | ||||
| FHMLS XI, L.L.C. | 0.2% | ||||
| Frazier Life Sciences XII, L.P. | 0.5% | ||||
| FHMLS XII, L.P. | 0.5% | ||||
| FHMLS XII, L.L.C. | 0.5% | ||||
| James N. Topper | 0.1% | ||||
| Patrick J. Heron | 0.1% | ||||
|
Mereo BioPharma Group plc
13G/A
Amendment 2
MREO · 589492107
|
0% |
2/13/2026
Event 12/31/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 0% | ||||
| FHMLSP, L.P. | 0% | ||||
| FHMLSP, L.L.C. | 0% | ||||
| Frazier Life Sciences X, L.P. | 0% | ||||
| FHMLS X, L.P. | 0% | ||||
| FHMLS X, L.L.C. | 0% | ||||
| Frazier Life Sciences XI, L.P. | 0% | ||||
| FHMLS XI, L.P. | 0% | ||||
| FHMLS XI, L.L.C. | 0% | ||||
| James N. Topper | 0% | ||||
| Patrick J. Heron | 0% | ||||
|
Aura Biosciences, Inc.
13G/A
Amendment 2
AURA · 05153U107
|
6.3% |
2/13/2026
Event 12/31/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 6.3% | ||||
| FHMLSP, L.P. | 6.3% | ||||
| FHMLSP, L.L.C. | 6.3% | ||||
| Frazier Life Sciences X, L.P. | 0.2% | ||||
| FHMLS X, L.P. | 0.2% | ||||
| FHMLS X, L.L.C. | 0.2% | ||||
| Frazier Life Sciences XI, L.P. | 0.5% | ||||
| FHMLS XI, L.P. | 0.5% | ||||
| FHMLS XI, L.L.C. | 0.5% | ||||
| Frazier Life Sciences XII, L.P. | 0.9% | ||||
| FHMLS XII, L.P. | 0.9% | ||||
| FHMLS XII, L.L.C. | 0.9% | ||||
| James N. Topper | 0.2% | ||||
| Patrick J. Heron | 0.2% | ||||
|
Lexeo Therapeutics, Inc.
13G/A
Amendment 2
LXEO · 52886X107
|
5.1% |
2/13/2026
Event 12/31/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 5.1% | ||||
| FHMLSP, L.P. | 5.1% | ||||
| FHMLSP, L.L.C. | 5.1% | ||||
| Frazier Life Sciences X, L.P. | 0.1% | ||||
| FHMLS X, L.P. | 0.1% | ||||
| FHMLS X, L.L.C. | 0.1% | ||||
| Frazier Life Sciences XI, L.P. | 0.3% | ||||
| FHMLS XI, L.P. | 0.3% | ||||
| FHMLS XI, L.L.C. | 0.3% | ||||
| Frazier Life Sciences XII, L.P. | 0.6% | ||||
| FHMLS XII, L.P. | 0.6% | ||||
| FHMLS XII, L.L.C. | 0.6% | ||||
| James N. Topper | 0.1% | ||||
| Patrick J. Heron | 0.1% | ||||
|
Palvella Therapeutics, Inc.
13G/A
Amendment 3
PVLA · 697947109
|
6.0% |
2/13/2026
Event 12/31/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 6.0% | ||||
| FHMLSP, L.P. | 6.0% | ||||
| FHMLSP, L.L.C. | 6.0% | ||||
| Frazier Life Sciences X, L.P. | 0% | ||||
| FHMLS X, L.P. | 0% | ||||
| FHMLS X, L.L.C. | 0% | ||||
| Frazier Life Sciences XI, L.P. | 0.1% | ||||
| FHMLS XI, L.P. | 0.1% | ||||
| FHMLS XI, L.L.C. | 0.1% | ||||
| Frazier Life Sciences XII, L.P. | 0% | ||||
| FHMLS XII, L.P. | 0% | ||||
| FHMLS XII, L.L.C. | 0% | ||||
| James N. Topper | 0% | ||||
| Patrick J. Heron | 0% | ||||
|
Xilio Therapeutics, Inc.
13G/A
Amendment 2
XLO · 98422T100
|
6.7% |
2/13/2026
Event 12/31/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 6.7% | ||||
| FHMLSP, L.P. | 6.7% | ||||
| FHMLSP, L.L.C. | 6.7% | ||||
| Frazier Life Sciences X, L.P. | 0.2% | ||||
| FHMLS X, L.P. | 0.2% | ||||
| FHMLS X, L.L.C. | 0.2% | ||||
| Frazier Life Sciences XI, L.P. | 0.6% | ||||
| FHMLS XI, L.P. | 0.6% | ||||
| FHMLS XI, L.L.C. | 0.6% | ||||
| Frazier Life Sciences XII, L.P. | 1.0% | ||||
| FHMLS XII, L.P. | 1.0% | ||||
| FHMLS XII, L.L.C. | 1.0% | ||||
| James N. Topper | 0.2% | ||||
| Patrick J. Heron | 0.2% | ||||
|
Maze Therapeutics, Inc.
13G/A
Amendment 4
MAZE · 578784100
|
9.0% |
2/13/2026
Event 12/31/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 9.0% | ||||
| FHMLSP, L.P. | 9.0% | ||||
| FHMLSP, L.L.C. | 9.0% | ||||
| Frazier Life Sciences X, L.P. | 0.2% | ||||
| FHMLS X, L.P. | 0.2% | ||||
| FHMLS X, L.L.C. | 0.2% | ||||
| Frazier Life Sciences XI, L.P. | 0.3% | ||||
| FHMLS XI, L.P. | 0.3% | ||||
| FHMLS XI, L.L.C. | 0.3% | ||||
| Frazier Life Sciences XII, L.P. | 0% | ||||
| FHMLS XII, L.P. | 0% | ||||
| FHMLS XII, L.L.C. | 0% | ||||
| James N. Topper | 0.2% | ||||
| Patrick J. Heron | 0.2% | ||||
|
Savara Inc.
13G/A
Amendment 3
SVRA · 805111101
|
4.1% |
2/13/2026
Event 12/31/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 4.1% | ||||
| FHMLSP, L.P. | 4.1% | ||||
| FHMLSP, L.L.C. | 4.1% | ||||
| Frazier Life Sciences X, L.P. | 0.1% | ||||
| FHMLS X, L.P. | 0.1% | ||||
| FHMLS X, L.L.C. | 0.1% | ||||
| Frazier Life Sciences XI, L.P. | 0.6% | ||||
| FHMLS XI, L.P. | 0.6% | ||||
| FHMLS XI, L.L.C. | 0.6% | ||||
| James N. Topper | 0.1% | ||||
| Patrick J. Heron | 0.1% | ||||
|
MacroGenics, Inc.
13G/A
Amendment 2
MGNX · 556099109
|
0% |
2/13/2026
Event 12/31/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 0% | ||||
| FHMLSP, L.P. | 0% | ||||
| FHMLSP, L.L.C. | 0% | ||||
| Frazier Life Sciences X, L.P. | 0% | ||||
| FHMLS X, L.P. | 0% | ||||
| FHMLS X, L.L.C. | 0% | ||||
| Frazier Life Sciences XI, L.P. | 0% | ||||
| FHMLS XI, L.P. | 0% | ||||
| FHMLS XI, L.L.C. | 0% | ||||
| James N. Topper | 0% | ||||
| Patrick J. Heron | 0% | ||||
|
Vor Biopharma Inc.
13G
VOR · 929033207
|
5.8% |
12/19/2025
Event 12/18/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 5.8% | ||||
| FHMLSP, L.P. | 5.8% | ||||
| FHMLSP, L.L.C. | 5.8% | ||||
| Frazier Life Sciences XI, L.P. | 0.1% | ||||
| FHMLS XI, L.P. | 0.1% | ||||
| FHMLS XI, L.L.C. | 0.1% | ||||
| Frazier Life Sciences XII, L.P. | 0.7% | ||||
| FHMLS XII, L.P. | 0.7% | ||||
| FHMLS XII, L.L.C. | 0.7% | ||||
|
iBio, Inc.
13G
IBIO · 451033708
|
8.7% |
12/16/2025
Event 12/9/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 8.7% | ||||
| FHMLSP, L.P. | 8.7% | ||||
| FHMLSP, L.L.C. | 8.7% | ||||
|
Adverum Biotechnologies, Inc.
13G/A
Amendment 3
ADVM · 00773U207
|
0% |
12/9/2025
Event 12/9/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 0% | ||||
| FHMLSP, L.P. | 0% | ||||
| FHMLSP, L.L.C. | 0% | ||||
| Frazier Life Sciences X, L.P. | 0% | ||||
| FHMLS X, L.P. | 0% | ||||
| FHMLS X, L.L.C. | 0% | ||||
| Frazier Life Sciences XI, L.P. | 0% | ||||
| FHMLS XI, L.P. | 0% | ||||
| FHMLS XI, L.L.C. | 0% | ||||
| Frazier Life Sciences XII, L.P. | 0% | ||||
| FHMLS XII, L.P. | 0% | ||||
| FHMLS XII, L.L.C. | 0% | ||||
| James N. Topper | 0% | ||||
| Patrick J. Heron | 0% | ||||
|
Adverum Biotechnologies, Inc.
13G/A
Amendment 2
ADVM · 00773U207
|
19.4% |
11/28/2025
Event 11/25/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 19.4% | ||||
| FHMLSP, L.P. | 19.4% | ||||
| FHMLSP, L.L.C. | 19.4% | ||||
| Frazier Life Sciences X, L.P. | 1.0% | ||||
| FHMLS X, L.P. | 1.0% | ||||
| FHMLS X, L.L.C. | 1.0% | ||||
| Frazier Life Sciences XI, L.P. | 2.3% | ||||
| FHMLS XI, L.P. | 2.3% | ||||
| FHMLS XI, L.L.C. | 2.3% | ||||
| Frazier Life Sciences XII, L.P. | 2.4% | ||||
| FHMLS XII, L.P. | 2.4% | ||||
| FHMLS XII, L.L.C. | 2.4% | ||||
| James N. Topper | 1.0% | ||||
| Patrick J. Heron | 1.0% | ||||
|
Trevi Therapeutics, Inc.
13G/A
Amendment 5
TRVI · 89532M101
|
7.0% |
11/14/2025
Event 9/30/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 7.0% | ||||
| FHMLSP, L.P. | 7.0% | ||||
| FHMLSP, L.L.C. | 7.0% | ||||
| Frazier Life Sciences X, L.P. | 0.3% | ||||
| FHMLS X, L.P. | 0.3% | ||||
| FHMLS X, L.L.C. | 0.3% | ||||
| Frazier Life Sciences XI, L.P. | 1.1% | ||||
| FHMLS XI, L.P. | 1.1% | ||||
| FHMLS XI, L.L.C. | 1.1% | ||||
| James N. Topper | 0.3% | ||||
| Patrick J. Heron | 0.3% | ||||
| Albert Cha | 0% | ||||
| James Brush | 0% | ||||
| Daniel Estes | 0% | ||||
|
Jade Biosciences, Inc.
13G/A
Amendment 2
JBIO · 008064206
|
4.2% |
11/14/2025
Event 9/30/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 4.2% | ||||
| FHMLSP, L.P. | 4.2% | ||||
| FHMLSP, L.L.C. | 4.2% | ||||
| Frazier Life Sciences X, L.P. | 0% | ||||
| FHMLS X, L.P. | 0% | ||||
| FHMLS X, L.L.C. | 0% | ||||
| Frazier Life Sciences XI, L.P. | 0.1% | ||||
| FHMLS XI, L.P. | 0.1% | ||||
| FHMLS XI, L.L.C. | 0.1% | ||||
| James N. Topper | 0% | ||||
| Patrick J. Heron | 0% | ||||
|
Phathom Pharmaceuticals, Inc.
13D/A
Amendment 11
PHAT · 71722W107
|
8.6% |
11/4/2025
Event 11/1/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 7.5% | ||||
| FHMLSP, L.P. | 7.5% | ||||
| FHMLSP, L.L.C. | 7.5% | ||||
| Frazier Life Sciences X, L.P. | 0.1% | ||||
| FHMLS X, L.P. | 0.1% | ||||
| FHMLS X, L.L.C. | 0.1% | ||||
| Frazier Life Sciences XI, L.P. | 1.4% | ||||
| FHMLS XI, L.P. | 1.4% | ||||
| FHMLS XI, L.L.C. | 1.4% | ||||
| Frazier Life Sciences IX, L.P. | 8.2% | ||||
| FHMLS IX, L.P. | 8.2% | ||||
| FHMLS IX, L.L.C. | 8.2% | ||||
| Frazier Life Sciences XII, L.P. | 0.4% | ||||
| FHMLS XII, L.P. | 0.4% | ||||
| FHMLS XII, L.L.C. | 0.4% | ||||
| James N. Topper | 8.6% | ||||
| Patrick J. Heron | 8.4% | ||||
|
KalVista Pharmaceuticals, Inc.
13D/A
Amendment 7
KALV · 483497103
|
6.9% |
11/4/2025
Event 11/1/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 6.9% | ||||
| FHMLSP, L.P. | 6.9% | ||||
| FHMLSP, L.L.C. | 6.9% | ||||
| Frazier Life Sciences X, L.P. | 2.3% | ||||
| FHMLS X, L.P. | 2.3% | ||||
| FHMLS X, L.L.C. | 2.3% | ||||
| Frazier Life Sciences XI, L.P. | 0.8% | ||||
| FHMLS XI, L.P. | 0.8% | ||||
| FHMLS XI, L.L.C. | 0.8% | ||||
| James N. Topper | 2.3% | ||||
| Patrick J. Heron | 2.3% | ||||
|
MBX Biosciences, Inc.
13D/A
Amendment 2
MBX · 55287L101
|
11.7% |
9/30/2025
Event 9/26/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 2.5% | ||||
| FHMLSP, L.P. | 2.5% | ||||
| FHMLSP, L.L.C. | 2.5% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 0.7% | ||||
| FHMLSP Overage, L.P. | 0.7% | ||||
| FHMLSP Overage, L.L.C. | 0.7% | ||||
| Frazier Life Sciences X, L.P. | 11.7% | ||||
| FHMLS X, L.P. | 11.7% | ||||
| FHMLS X, L.L.C. | 11.7% | ||||
| Frazier Life Sciences XI, L.P. | 0% | ||||
| FHMLS XI, L.P. | 0% | ||||
| FHMLS XI, L.L.C. | 0% | ||||
| James N. Topper | 11.7% | ||||
| Patrick J. Heron | 11.7% | ||||
|
HilleVax, Inc.
13D/A
Amendment 5
HLVX · 43157M102
|
0% |
9/17/2025
Event 9/17/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 0% | ||||
| FHMLSP, L.P. | 0% | ||||
| FHMLSP, L.L.C. | 0% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 0% | ||||
| FHMLSP Overage, L.P. | 0% | ||||
| FHMLSP Overage, L.L.C. | 0% | ||||
| Frazier Life Sciences X, L.P. | 0% | ||||
| FHMLS X, L.P. | 0% | ||||
| FHMLS X, L.L.C. | 0% | ||||
| Frazier Life Sciences XI, L.P. | 0% | ||||
| FHMLS XI, L.P. | 0% | ||||
| FHMLS XI, L.L.C. | 0% | ||||
| James N. Topper | 0% | ||||
| Patrick J. Heron | 0% | ||||
| Albert Cha | 0% | ||||
| James Brush | 0% | ||||
| Daniel Estes | 0% | ||||
|
MBX Biosciences, Inc.
13D/A
Amendment 1
MBX · 55287L101
|
13.6% |
8/20/2025
Event 8/18/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 3.3% | ||||
| FHMLSP, L.P. | 3.3% | ||||
| FHMLSP, L.L.C. | 3.3% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.0% | ||||
| FHMLSP Overage, L.P. | 1.0% | ||||
| FHMLSP Overage, L.L.C. | 1.0% | ||||
| Frazier Life Sciences X, L.P. | 13.6% | ||||
| FHMLS X, L.P. | 13.6% | ||||
| FHMLS X, L.L.C. | 13.6% | ||||
| Frazier Life Sciences XI, L.P. | 0% | ||||
| FHMLS XI, L.P. | 0% | ||||
| FHMLS XI, L.L.C. | 0% | ||||
| James N. Topper | 13.6% | ||||
| Patrick J. Heron | 13.6% | ||||
| Albert Cha | 0% | ||||
| James Brush | 0% | ||||
| Daniel Estes | 0% | ||||
|
KalVista Pharmaceuticals, Inc.
13D/A
Amendment 6
KALV · 483497103
|
4.8% |
8/20/2025
Event 8/18/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 4.8% | ||||
| FHMLSP, L.P. | 4.8% | ||||
| FHMLSP, L.L.C. | 4.8% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.9% | ||||
| FHMLSP Overage, L.P. | 1.9% | ||||
| FHMLSP Overage, L.L.C. | 1.9% | ||||
| Frazier Life Sciences X, L.P. | 2.3% | ||||
| FHMLS X, L.P. | 2.3% | ||||
| FHMLS X, L.L.C. | 2.3% | ||||
| Frazier Life Sciences XI, L.P. | 0.8% | ||||
| FHMLS XI, L.P. | 0.8% | ||||
| FHMLS XI, L.L.C. | 0.8% | ||||
| James N. Topper | 2.3% | ||||
| Patrick J. Heron | 2.3% | ||||
| Albert Cha | 0% | ||||
| James Brush | 0% | ||||
| Daniel Estes | 0% | ||||
|
Phathom Pharmaceuticals, Inc.
13D/A
Amendment 10
PHAT · 71722W107
|
8.6% |
8/20/2025
Event 8/18/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 6.0% | ||||
| FHMLSP, L.P. | 6.0% | ||||
| FHMLSP, L.L.C. | 6.0% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.6% | ||||
| FHMLSP Overage, L.P. | 1.6% | ||||
| FHMLSP Overage, L.L.C. | 1.6% | ||||
| Frazier Life Sciences X, L.P. | 0.1% | ||||
| FHMLS X, L.P. | 0.1% | ||||
| FHMLS X, L.L.C. | 0.1% | ||||
| Frazier Life Sciences XI, L.P. | 1.4% | ||||
| FHMLS XI, L.P. | 1.4% | ||||
| FHMLS XI, L.L.C. | 1.4% | ||||
| Frazier Life Sciences IX, L.P. | 8.2% | ||||
| FHMLS IX, L.P. | 8.2% | ||||
| FHMLS IX, L.L.C. | 8.2% | ||||
| Frazier Life Sciences XII, L.P. | 0.4% | ||||
| FHMLS XII, L.P. | 0.4% | ||||
| FHMLS XII, L.L.C. | 0.4% | ||||
| James N. Topper | 8.6% | ||||
| Patrick J. Heron | 8.4% | ||||
| Albert Cha | 0% | ||||
| James Brush | 0% | ||||
| Daniel Estes | 0% | ||||
|
Xilio Therapeutics, Inc.
13G/A
Amendment 1
XLO · 98422T100
|
9.9% |
8/14/2025
Event 6/30/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 9.9% | ||||
| FHMLSP, L.P. | 9.9% | ||||
| FHMLSP, L.L.C. | 9.9% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 4.4% | ||||
| FHMLSP Overage, L.P. | 4.4% | ||||
| FHMLSP Overage, L.L.C. | 4.4% | ||||
| Frazier Life Sciences X, L.P. | 0.6% | ||||
| FHMLS X, L.P. | 0.6% | ||||
| FHMLS X, L.L.C. | 0.6% | ||||
| Frazier Life Sciences XI, L.P. | 1.7% | ||||
| FHMLS XI, L.P. | 1.7% | ||||
| FHMLS XI, L.L.C. | 1.7% | ||||
| Frazier Life Sciences XII, L.P. | 2.9% | ||||
| FHMLS XII, L.P. | 2.9% | ||||
| FHMLS XII, L.L.C. | 2.9% | ||||
| James N. Topper | 0.6% | ||||
| Patrick J. Heron | 0.6% | ||||
| Albert Cha | 0% | ||||
| James Brush | 0% | ||||
| Daniel Estes | 0% | ||||
|
Jade Biosciences, Inc.
13G/A
Amendment 1
JBIO · 008064206
|
4.2% |
8/14/2025
Event 6/30/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 4.2% | ||||
| FHMLSP, L.P. | 4.2% | ||||
| FHMLSP, L.L.C. | 4.2% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.2% | ||||
| FHMLSP Overage, L.P. | 1.2% | ||||
| FHMLSP Overage, L.L.C. | 1.2% | ||||
| Frazier Life Sciences X, L.P. | 0% | ||||
| FHMLS X, L.P. | 0% | ||||
| FHMLS X, L.L.C. | 0% | ||||
| Frazier Life Sciences XI, L.P. | 0.1% | ||||
| FHMLS XI, L.P. | 0.1% | ||||
| FHMLS XI, L.L.C. | 0.1% | ||||
| James N. Topper | 0% | ||||
| Patrick J. Heron | 0% | ||||
| Albert Cha | 0% | ||||
| James Brush | 0% | ||||
| Daniel Estes | 0% | ||||
|
Aura Biosciences, Inc.
13G/A
Amendment 1
AURA · 05153U107
|
5.0% |
8/14/2025
Event 6/30/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 5.0% | ||||
| FHMLSP, L.P. | 5.0% | ||||
| FHMLSP, L.L.C. | 5.0% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.5% | ||||
| FHMLSP Overage, L.P. | 1.5% | ||||
| FHMLSP Overage, L.L.C. | 1.5% | ||||
| Frazier Life Sciences X, L.P. | 0.2% | ||||
| FHMLS X, L.P. | 0.2% | ||||
| FHMLS X, L.L.C. | 0.2% | ||||
| Frazier Life Sciences XI, L.P. | 0.6% | ||||
| FHMLS XI, L.P. | 0.6% | ||||
| FHMLS XI, L.L.C. | 0.6% | ||||
| Frazier Life Sciences XII, L.P. | 1.0% | ||||
| FHMLS XII, L.P. | 1.0% | ||||
| FHMLS XII, L.L.C. | 1.0% | ||||
| James N. Topper | 0.2% | ||||
| Patrick J. Heron | 0.2% | ||||
| Albert Cha | 0% | ||||
| James Brush | 0% | ||||
| Daniel Estes | 0% | ||||
|
Maze Therapeutics, Inc.
13G/A
Amendment 3
MAZE · 578784100
|
7.7% |
8/14/2025
Event 6/30/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 7.7% | ||||
| FHMLSP, L.P. | 7.7% | ||||
| FHMLSP, L.L.C. | 7.7% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 2.3% | ||||
| FHMLSP Overage, L.P. | 2.3% | ||||
| FHMLSP Overage, L.L.C. | 2.3% | ||||
| Frazier Life Sciences X, L.P. | 0.2% | ||||
| FHMLS X, L.P. | 0.2% | ||||
| FHMLS X, L.L.C. | 0.2% | ||||
| Frazier Life Sciences XI, L.P. | 0.3% | ||||
| FHMLS XI, L.P. | 0.3% | ||||
| FHMLS XI, L.L.C. | 0.3% | ||||
| James N. Topper | 0.2% | ||||
| Patrick J. Heron | 0.2% | ||||
| Albert Cha | 0% | ||||
| James Brush | 0% | ||||
| Daniel Estes | 0% | ||||
|
Palvella Therapeutics, Inc.
13G/A
Amendment 2
PVLA · 697947109
|
4.9% |
8/14/2025
Event 6/30/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 4.9% | ||||
| FHMLSP, L.P. | 4.9% | ||||
| FHMLSP, L.L.C. | 4.9% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.5% | ||||
| FHMLSP Overage, L.P. | 1.5% | ||||
| FHMLSP Overage, L.L.C. | 1.5% | ||||
| Frazier Life Sciences X, L.P. | 0% | ||||
| FHMLS X, L.P. | 0% | ||||
| FHMLS X, L.L.C. | 0% | ||||
| Frazier Life Sciences XI, L.P. | 0.1% | ||||
| FHMLS XI, L.P. | 0.1% | ||||
| FHMLS XI, L.L.C. | 0.1% | ||||
| Frazier Life Sciences XII, L.P. | 0% | ||||
| FHMLS XII, L.P. | 0% | ||||
| FHMLS XII, L.L.C. | 0% | ||||
| James N. Topper | 0% | ||||
| Patrick J. Heron | 0% | ||||
| Albert Cha | 0% | ||||
| James Brush | 0% | ||||
| Daniel Estes | 0% | ||||
|
Lexeo Therapeutics, Inc.
13G/A
Amendment 1
LXEO · 52886X107
|
5.7% |
8/14/2025
Event 6/30/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 5.7% | ||||
| FHMLSP, L.P. | 5.7% | ||||
| FHMLSP, L.L.C. | 5.7% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.2% | ||||
| FHMLSP Overage, L.P. | 1.2% | ||||
| FHMLSP Overage, L.L.C. | 1.2% | ||||
| Frazier Life Sciences X, L.P. | 0.2% | ||||
| FHMLS X, L.P. | 0.2% | ||||
| FHMLS X, L.L.C. | 0.2% | ||||
| Frazier Life Sciences XI, L.P. | 0.4% | ||||
| FHMLS XI, L.P. | 0.4% | ||||
| FHMLS XI, L.L.C. | 0.4% | ||||
| Frazier Life Sciences XII, L.P. | 0.8% | ||||
| FHMLS XII, L.P. | 0.8% | ||||
| FHMLS XII, L.L.C. | 0.8% | ||||
| James N. Topper | 0.2% | ||||
| Patrick J. Heron | 0.2% | ||||
| Albert Cha | 0% | ||||
| James Brush | 0% | ||||
| Daniel Estes | 0% | ||||
|
Mereo BioPharma Group plc
13G/A
Amendment 1
MREO · 589492107
|
4.1% |
8/14/2025
Event 6/30/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 4.1% | ||||
| FHMLSP, L.P. | 4.1% | ||||
| FHMLSP, L.L.C. | 4.1% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.1% | ||||
| FHMLSP Overage, L.P. | 1.1% | ||||
| FHMLSP Overage, L.L.C. | 1.1% | ||||
| Frazier Life Sciences X, L.P. | 0.2% | ||||
| FHMLS X, L.P. | 0.2% | ||||
| FHMLS X, L.L.C. | 0.2% | ||||
| Frazier Life Sciences XI, L.P. | 0.5% | ||||
| FHMLS XI, L.P. | 0.5% | ||||
| FHMLS XI, L.L.C. | 0.5% | ||||
| James N. Topper | 0.2% | ||||
| Patrick J. Heron | 0.2% | ||||
| Albert Cha | 0% | ||||
| James Brush | 0% | ||||
| Daniel Estes | 0% | ||||
|
Savara Inc.
13G/A
Amendment 2
SVRA · 805111101
|
3.9% |
8/14/2025
Event 6/30/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 3.9% | ||||
| FHMLSP, L.P. | 3.9% | ||||
| FHMLSP, L.L.C. | 3.9% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.7% | ||||
| FHMLSP Overage, L.P. | 1.7% | ||||
| FHMLSP Overage, L.L.C. | 1.7% | ||||
| Frazier Life Sciences X, L.P. | 0.2% | ||||
| FHMLS X, L.P. | 0.2% | ||||
| FHMLS X, L.L.C. | 0.2% | ||||
| Frazier Life Sciences XI, L.P. | 0.9% | ||||
| FHMLS XI, L.P. | 0.9% | ||||
| FHMLS XI, L.L.C. | 0.9% | ||||
| James N. Topper | 0.2% | ||||
| Patrick J. Heron | 0.2% | ||||
| Albert Cha | 0% | ||||
| James Brush | 0% | ||||
| Daniel Estes | 0% | ||||
|
Disc Medicine, Inc.
13G/A
Amendment 1
IRON · 254604101
|
3.0% |
8/14/2025
Event 6/30/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 3.0% | ||||
| FHMLSP, L.P. | 3.0% | ||||
| FHMLSP, L.L.C. | 3.0% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 0.9% | ||||
| FHMLSP Overage, L.P. | 0.9% | ||||
| FHMLSP Overage, L.L.C. | 0.9% | ||||
| Frazier Life Sciences X, L.P. | 0.2% | ||||
| FHMLS X, L.P. | 0.2% | ||||
| FHMLS X, L.L.C. | 0.2% | ||||
| Frazier Life Sciences XI, L.P. | 0.8% | ||||
| FHMLS XI, L.P. | 0.8% | ||||
| FHMLS XI, L.L.C. | 0.8% | ||||
| James N. Topper | 0.2% | ||||
| Patrick J. Heron | 0.2% | ||||
| Albert Cha | 0% | ||||
| James Brush | 0% | ||||
| Daniel Estes | 0% | ||||
|
Erasca, Inc.
13G/A
Amendment 2
ERAS · 29479A108
|
5.3% |
8/14/2025
Event 6/30/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 5.3% | ||||
| FHMLSP, L.P. | 5.3% | ||||
| FHMLSP, L.L.C. | 5.3% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 0.8% | ||||
| FHMLSP Overage, L.P. | 0.8% | ||||
| FHMLSP Overage, L.L.C. | 0.8% | ||||
| Frazier Life Sciences X, L.P. | 0.6% | ||||
| FHMLS X, L.P. | 0.6% | ||||
| FHMLS X, L.L.C. | 0.6% | ||||
| Frazier Life Sciences XI, L.P. | 1.3% | ||||
| FHMLS XI, L.P. | 1.3% | ||||
| FHMLS XI, L.L.C. | 1.3% | ||||
| James N. Topper | 0.6% | ||||
| Patrick J. Heron | 0.6% | ||||
| Albert Cha | 0% | ||||
| James Brush | 0% | ||||
| Daniel Estes | 0% | ||||
|
Elevation Oncology, Inc.
13G/A
Amendment 2
ELEV · 28623U101
|
0% |
8/14/2025
Event 7/23/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 0% | ||||
| FHMLSP, L.P. | 0% | ||||
| FHMLSP, L.L.C. | 0% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 0% | ||||
| FHMLSP Overage, L.P. | 0% | ||||
| FHMLSP Overage, L.L.C. | 0% | ||||
| Frazier Life Sciences X, L.P. | 0% | ||||
| FHMLS X, L.P. | 0% | ||||
| FHMLS X, L.L.C. | 0% | ||||
| Frazier Life Sciences XI, L.P. | 0% | ||||
| FHMLS XI, L.P. | 0% | ||||
| FHMLS XI, L.L.C. | 0% | ||||
| James N. Topper | 0% | ||||
| Patrick J. Heron | 0% | ||||
| Albert Cha | 0% | ||||
| James Brush | 0% | ||||
| Daniel Estes | 0% | ||||
|
Adverum Biotechnologies, Inc.
13G/A
Amendment 1
ADVM · 00773U207
|
5.4% |
8/14/2025
Event 8/12/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 5.4% | ||||
| FHMLSP, L.P. | 5.4% | ||||
| FHMLSP, L.L.C. | 5.4% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 2.0% | ||||
| FHMLSP Overage, L.P. | 2.0% | ||||
| FHMLSP Overage, L.L.C. | 2.0% | ||||
| Frazier Life Sciences X, L.P. | 0.6% | ||||
| FHMLS X, L.P. | 0.6% | ||||
| FHMLS X, L.L.C. | 0.6% | ||||
| Frazier Life Sciences XI, L.P. | 1.3% | ||||
| FHMLS XI, L.P. | 1.3% | ||||
| FHMLS XI, L.L.C. | 1.3% | ||||
| Frazier Life Sciences XII, L.P. | 0.6% | ||||
| FHMLS XII, L.P. | 0.6% | ||||
| FHMLS XII, L.L.C. | 0.6% | ||||
| James N. Topper | 0.6% | ||||
| Patrick J. Heron | 0.6% | ||||
| Albert Cha | 0% | ||||
| James Brush | 0% | ||||
| Daniel Estes | 0% | ||||
|
MacroGenics, Inc.
13G/A
Amendment 1
MGNX · 556099109
|
2.5% |
8/14/2025
Event 6/30/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 2.5% | ||||
| FHMLSP, L.P. | 2.5% | ||||
| FHMLSP, L.L.C. | 2.5% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.5% | ||||
| FHMLSP Overage, L.P. | 1.5% | ||||
| FHMLSP Overage, L.L.C. | 1.5% | ||||
| Frazier Life Sciences X, L.P. | 0.2% | ||||
| FHMLS X, L.P. | 0.2% | ||||
| FHMLS X, L.L.C. | 0.2% | ||||
| Frazier Life Sciences XI, L.P. | 0.9% | ||||
| FHMLS XI, L.P. | 0.9% | ||||
| FHMLS XI, L.L.C. | 0.9% | ||||
| James N. Topper | 0.2% | ||||
| Patrick J. Heron | 0.2% | ||||
| Albert Cha | 0% | ||||
| James Brush | 0% | ||||
| Daniel Estes | 0% | ||||
|
Xilio Therapeutics, Inc.
13G
XLO · 98422T100
|
9.9% |
6/12/2025
Event 6/5/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 6.3% | ||||
| FHMLSP, L.P. | 6.3% | ||||
| FHMLSP, L.L.C. | 6.3% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 2.0% | ||||
| FHMLSP Overage, L.P. | 2.0% | ||||
| FHMLSP Overage, L.L.C. | 2.0% | ||||
| Frazier Life Sciences X, L.P. | 0.3% | ||||
| FHMLS X, L.P. | 0.3% | ||||
| FHMLS X, L.L.C. | 0.3% | ||||
| Frazier Life Sciences XI, L.P. | 0.7% | ||||
| FHMLS XI, L.P. | 0.7% | ||||
| FHMLS XI, L.L.C. | 0.7% | ||||
| Frazier Life Sciences XII, L.P. | 1.3% | ||||
| FHMLS XII, L.P. | 1.3% | ||||
| FHMLS XII, L.L.C. | 1.3% | ||||
| James N. Topper | 9.9% | ||||
| Patrick J. Heron | 9.9% | ||||
| Albert Cha | 8.1% | ||||
| James Brush | 8.1% | ||||
| Daniel Estes | 2.0% | ||||
|
Lexeo Therapeutics, Inc.
13G
LXEO · 52886X107
|
9.9% |
6/4/2025
Event 5/28/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 6.8% | ||||
| FHMLSP, L.P. | 6.8% | ||||
| FHMLSP, L.L.C. | 6.8% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.5% | ||||
| FHMLSP Overage, L.P. | 1.5% | ||||
| FHMLSP Overage, L.L.C. | 1.5% | ||||
| Frazier Life Sciences X, L.P. | 0.2% | ||||
| FHMLS X, L.P. | 0.2% | ||||
| FHMLS X, L.L.C. | 0.2% | ||||
| Frazier Life Sciences XI, L.P. | 0.6% | ||||
| FHMLS XI, L.P. | 0.6% | ||||
| FHMLS XI, L.L.C. | 0.6% | ||||
| Frazier Life Sciences XII, L.P. | 1.0% | ||||
| FHMLS XII, L.P. | 1.0% | ||||
| FHMLS XII, L.L.C. | 1.0% | ||||
| James N. Topper | 9.9% | ||||
| Patrick J. Heron | 9.9% | ||||
| Albert Cha | 8.3% | ||||
| James Brush | 8.3% | ||||
| Daniel Estes | 1.5% | ||||
|
Aura Biosciences, Inc.
13G
AURA · 05153U107
|
9.9% |
5/23/2025
Event 5/16/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 6.1% | ||||
| FHMLSP, L.P. | 6.1% | ||||
| FHMLSP, L.L.C. | 6.1% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.8% | ||||
| FHMLSP Overage, L.P. | 1.8% | ||||
| FHMLSP Overage, L.L.C. | 1.8% | ||||
| Frazier Life Sciences X, L.P. | 0.3% | ||||
| FHMLS X, L.P. | 0.3% | ||||
| FHMLS X, L.L.C. | 0.3% | ||||
| Frazier Life Sciences XI, L.P. | 0.7% | ||||
| FHMLS XI, L.P. | 0.7% | ||||
| FHMLS XI, L.L.C. | 0.7% | ||||
| Frazier Life Sciences XII, L.P. | 1.2% | ||||
| FHMLS XII, L.P. | 1.2% | ||||
| FHMLS XII, L.L.C. | 1.2% | ||||
| James N. Topper | 9.9% | ||||
| Patrick J. Heron | 9.9% | ||||
| Albert Cha | 7.9% | ||||
| James Brush | 7.9% | ||||
| Daniel Estes | 1.9% | ||||
|
Trevi Therapeutics, Inc.
13G/A
Amendment 4
TRVI · 89532M101
|
10.6% |
5/15/2025
Event 3/31/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 8.8% | ||||
| FHMLSP, L.P. | 8.8% | ||||
| FHMLSP, L.L.C. | 8.8% | ||||
| Frazier Life Sciences X, L.P. | 0.4% | ||||
| FHMLS X, L.P. | 0.4% | ||||
| FHMLS X, L.L.C. | 0.4% | ||||
| Frazier Life Sciences XI, L.P. | 1.4% | ||||
| FHMLS XI, L.P. | 1.4% | ||||
| FHMLS XI, L.L.C. | 1.4% | ||||
| James N. Topper | 10.6% | ||||
| Patrick J. Heron | 10.6% | ||||
| Albert Cha | 8.8% | ||||
| James Brush | 8.8% | ||||
| Daniel Estes | 1.4% | ||||
|
Savara Inc.
13G/A
Amendment 1
SVRA · 805111101
|
6.6% |
5/15/2025
Event 3/31/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 3.9% | ||||
| FHMLSP, L.P. | 3.9% | ||||
| FHMLSP, L.L.C. | 3.9% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.7% | ||||
| FHMLSP Overage, L.P. | 1.7% | ||||
| FHMLSP Overage, L.L.C. | 1.7% | ||||
| Frazier Life Sciences X, L.P. | 0.2% | ||||
| FHMLS X, L.P. | 0.2% | ||||
| FHMLS X, L.L.C. | 0.2% | ||||
| Frazier Life Sciences XI, L.P. | 0.9% | ||||
| FHMLS XI, L.P. | 0.9% | ||||
| FHMLS XI, L.L.C. | 0.9% | ||||
| James N. Topper | 6.6% | ||||
| Patrick J. Heron | 6.6% | ||||
| Albert Cha | 5.6% | ||||
| James Brush | 5.6% | ||||
| Daniel Estes | 0.9% | ||||
|
Erasca, Inc.
13G/A
Amendment 1
ERAS · 29479A108
|
8.0% |
5/15/2025
Event 3/31/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 5.3% | ||||
| FHMLSP, L.P. | 5.3% | ||||
| FHMLSP, L.L.C. | 5.3% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 0.8% | ||||
| FHMLSP Overage, L.P. | 0.8% | ||||
| FHMLSP Overage, L.L.C. | 0.8% | ||||
| Frazier Life Sciences X, L.P. | 0.6% | ||||
| FHMLS X, L.P. | 0.6% | ||||
| FHMLS X, L.L.C. | 0.6% | ||||
| Frazier Life Sciences XI, L.P. | 1.3% | ||||
| FHMLS XI, L.P. | 1.3% | ||||
| FHMLS XI, L.L.C. | 1.3% | ||||
| James N. Topper | 8.0% | ||||
| Patrick J. Heron | 8.0% | ||||
| Albert Cha | 6.1% | ||||
| James Brush | 6.1% | ||||
| Daniel Estes | 1.3% | ||||
|
ORIC Pharmaceuticals, Inc.
13G/A
Amendment 1
ORIC · 68622P109
|
2.0% |
5/15/2025
Event 3/31/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 0.9% | ||||
| FHMLSP, L.P. | 0.9% | ||||
| FHMLSP, L.L.C. | 0.9% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 0.6% | ||||
| FHMLSP Overage, L.P. | 0.6% | ||||
| FHMLSP Overage, L.L.C. | 0.6% | ||||
| Frazier Life Sciences X, L.P. | 0.2% | ||||
| FHMLS X, L.P. | 0.2% | ||||
| FHMLS X, L.L.C. | 0.2% | ||||
| Frazier Life Sciences XI, L.P. | 0.4% | ||||
| FHMLS XI, L.P. | 0.4% | ||||
| FHMLS XI, L.L.C. | 0.4% | ||||
| James N. Topper | 2.0% | ||||
| Patrick J. Heron | 2.0% | ||||
| Albert Cha | 1.4% | ||||
| James Brush | 1.4% | ||||
| Daniel Estes | 0.4% | ||||
|
Palvella Therapeutics, Inc.
13G/A
Amendment 1
PVLA · 697947109
|
6.3% |
5/15/2025
Event 3/31/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 4.8% | ||||
| FHMLSP, L.P. | 4.8% | ||||
| FHMLSP, L.L.C. | 4.8% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.4% | ||||
| FHMLSP Overage, L.P. | 1.4% | ||||
| FHMLSP Overage, L.L.C. | 1.4% | ||||
| Frazier Life Sciences X, L.P. | 0% | ||||
| FHMLS X, L.P. | 0% | ||||
| FHMLS X, L.L.C. | 0% | ||||
| Frazier Life Sciences XI, L.P. | 0% | ||||
| FHMLS XI, L.P. | 0% | ||||
| FHMLS XI, L.L.C. | 0% | ||||
| James N. Topper | 6.3% | ||||
| Patrick J. Heron | 6.3% | ||||
| Albert Cha | 6.2% | ||||
| James Brush | 6.2% | ||||
| Daniel Estes | 0% | ||||
|
Phathom Pharmaceuticals, Inc.
13D/A
Amendment 9
PHAT · 71722W107
|
19.9% |
5/13/2025
Event 5/9/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 8.0% | ||||
| FHMLSP, L.P. | 8.0% | ||||
| FHMLSP, L.L.C. | 8.0% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 2.2% | ||||
| FHMLSP Overage, L.P. | 2.2% | ||||
| FHMLSP Overage, L.L.C. | 2.2% | ||||
| Frazier Life Sciences X, L.P. | 0.1% | ||||
| FHMLS X, L.P. | 0.1% | ||||
| FHMLS X, L.L.C. | 0.1% | ||||
| Frazier Life Sciences XI, L.P. | 1.4% | ||||
| FHMLS XI, L.P. | 1.4% | ||||
| FHMLS XI, L.L.C. | 1.4% | ||||
| Frazier Life Sciences IX, L.P. | 8.3% | ||||
| FHMLS IX, L.P. | 8.3% | ||||
| FHMLS IX, L.L.C. | 8.3% | ||||
| Frazier Life Sciences XII, L.P. | 0.3% | ||||
| FHMLS XII, L.P. | 0.3% | ||||
| FHMLS XII, L.L.C. | 0.3% | ||||
| James N. Topper | 19.9% | ||||
| Patrick J. Heron | 19.9% | ||||
| Albert Cha | 10.1% | ||||
| James Brush | 10.1% | ||||
| Daniel Estes | 1.7% | ||||
|
Jade Biosciences, Inc.
13G
JBIO · 008064206
|
5.5% |
5/5/2025
Event 4/28/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 4.2% | ||||
| FHMLSP, L.P. | 4.2% | ||||
| FHMLSP, L.L.C. | 4.2% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.2% | ||||
| FHMLSP Overage, L.P. | 1.2% | ||||
| FHMLSP Overage, L.L.C. | 1.2% | ||||
| Frazier Life Sciences X, L.P. | 0% | ||||
| FHMLS X, L.P. | 0% | ||||
| FHMLS X, L.L.C. | 0% | ||||
| Frazier Life Sciences XI, L.P. | 0.1% | ||||
| FHMLS XI, L.P. | 0.1% | ||||
| FHMLS XI, L.L.C. | 0.1% | ||||
| James N. Topper | 5.5% | ||||
| Patrick J. Heron | 5.5% | ||||
| Albert Cha | 5.4% | ||||
| James Brush | 5.4% | ||||
| Daniel Estes | 0.1% | ||||
|
Maze Therapeutics, Inc.
13G/A
Amendment 2
MAZE · 578784100
|
10.2% |
4/29/2025
Event 4/25/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 7.5% | ||||
| FHMLSP, L.P. | 7.5% | ||||
| FHMLSP, L.L.C. | 7.5% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 2.2% | ||||
| FHMLSP Overage, L.P. | 2.2% | ||||
| FHMLSP Overage, L.L.C. | 2.2% | ||||
| Frazier Life Sciences X, L.P. | 0.2% | ||||
| FHMLS X, L.P. | 0.2% | ||||
| FHMLS X, L.L.C. | 0.2% | ||||
| Frazier Life Sciences XI, L.P. | 0.3% | ||||
| FHMLS XI, L.P. | 0.3% | ||||
| FHMLS XI, L.L.C. | 0.3% | ||||
| James N. Topper | 10.2% | ||||
| Patrick J. Heron | 10.2% | ||||
| Albert Cha | 9.7% | ||||
| James Brush | 9.7% | ||||
| Daniel Estes | 0.3% | ||||
|
Maze Therapeutics, Inc.
13G/A
Amendment 1
MAZE · 578784100
|
9.4% |
4/29/2025
Event 3/31/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 7.0% | ||||
| FHMLSP, L.P. | 7.0% | ||||
| FHMLSP, L.L.C. | 7.0% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 2.1% | ||||
| FHMLSP Overage, L.P. | 2.1% | ||||
| FHMLSP Overage, L.L.C. | 2.1% | ||||
| Frazier Life Sciences X, L.P. | 0.2% | ||||
| FHMLS X, L.P. | 0.2% | ||||
| FHMLS X, L.L.C. | 0.2% | ||||
| Frazier Life Sciences XI, L.P. | 0.3% | ||||
| FHMLS XI, L.P. | 0.3% | ||||
| FHMLS XI, L.L.C. | 0.3% | ||||
| James N. Topper | 9.4% | ||||
| Patrick J. Heron | 9.4% | ||||
| Albert Cha | 9.0% | ||||
| James Brush | 9.0% | ||||
| Daniel Estes | 0.3% | ||||
|
Mereo BioPharma Group plc
13G
MREO · 589492107
|
5.1% |
4/4/2025
Event 4/1/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 3.5% | ||||
| FHMLSP, L.P. | 3.5% | ||||
| FHMLSP, L.L.C. | 3.5% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 0.9% | ||||
| FHMLSP Overage, L.P. | 0.9% | ||||
| FHMLSP Overage, L.L.C. | 0.9% | ||||
| Frazier Life Sciences X, L.P. | 0.2% | ||||
| FHMLS X, L.P. | 0.2% | ||||
| FHMLS X, L.L.C. | 0.2% | ||||
| Frazier Life Sciences XI, L.P. | 0.5% | ||||
| FHMLS XI, L.P. | 0.5% | ||||
| FHMLS XI, L.L.C. | 0.5% | ||||
| James N. Topper | 5.1% | ||||
| Patrick J. Heron | 5.1% | ||||
| Albert Cha | 4.4% | ||||
| James Brush | 4.4% | ||||
| Daniel Estes | 0.5% | ||||
|
AnaptysBio, Inc.
13G/A
Amendment 2
ANAB · 032724106
|
1.5% |
2/14/2025
Event 1/31/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 0.5% | ||||
| FHMLSP, L.P. | 0.5% | ||||
| FHMLSP, L.L.C. | 0.5% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 0.1% | ||||
| FHMLSP Overage, L.P. | 0.1% | ||||
| FHMLSP Overage, L.L.C. | 0.1% | ||||
| Frazier Life Sciences X, L.P. | 0.1% | ||||
| FHMLS X, L.P. | 0.1% | ||||
| FHMLS X, L.L.C. | 0.1% | ||||
| Frazier Life Sciences XI, L.P. | 0.1% | ||||
| FHMLS XI, L.P. | 0.1% | ||||
| FHMLS XI, L.L.C. | 0.1% | ||||
| Frazier Healthcare VII, L.P. | 0.4% | ||||
| Frazier Healthcare VII-A, L.P. | 0.1% | ||||
| FHM VII, L.P. | 0.5% | ||||
| FHM VII, L.L.C. | 0.5% | ||||
| James N. Topper | 1.5% | ||||
| Patrick J. Heron | 1.3% | ||||
| Albert Cha | 0.6% | ||||
| James Brush | 0.6% | ||||
| Daniel Estes | 0.1% | ||||
| Alan Frazier | 0.5% | ||||
| Nader Naini | 0.5% | ||||
| Nathan Every | 0.5% | ||||
| Brian Morfitt | 0.5% | ||||
|
AnaptysBio, Inc.
13G/A
Amendment 1
ANAB · 032724106
|
5.4% |
2/14/2025
Event 12/31/2024
|
|||
| Frazier Life Sciences Public Fund, L.P. | 2.0% | ||||
| FHMLSP, L.P. | 2.0% | ||||
| FHMLSP, L.L.C. | 2.0% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 0.3% | ||||
| FHMLSP Overage, L.P. | 0.3% | ||||
| FHMLSP Overage, L.L.C. | 0.3% | ||||
| Frazier Life Sciences X, L.P. | 0.3% | ||||
| FHMLS X, L.P. | 0.3% | ||||
| FHMLS X, L.L.C. | 0.3% | ||||
| Frazier Life Sciences XI, L.P. | 0.5% | ||||
| FHMLS XI, L.P. | 0.5% | ||||
| FHMLS XI, L.L.C. | 0.5% | ||||
| Frazier Healthcare VII, L.P. | 1.6% | ||||
| Frazier Healthcare VII-A, L.P. | 0.5% | ||||
| FHM VII, L.P. | 2.1% | ||||
| FHM VII, L.L.C. | 2.1% | ||||
| James N. Topper | 5.4% | ||||
| Patrick J. Heron | 5.2% | ||||
| Albert Cha | 2.3% | ||||
| James Brush | 2.3% | ||||
| Daniel Estes | 0.5% | ||||
| Alan Frazier | 2.1% | ||||
| Nader Naini | 2.1% | ||||
| Nathan Every | 2.1% | ||||
| Brian Morfitt | 2.1% | ||||
|
Eledon Pharmaceuticals, Inc.
13G/A
Amendment 1
ELDN · 28617K101
|
2.0% |
2/14/2025
Event 12/31/2024
|
|||
| Frazier Life Sciences Public Fund, L.P. | 1.5% | ||||
| FHMLSP, L.P. | 1.5% | ||||
| FHMLSP, L.L.C. | 1.5% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 0.4% | ||||
| FHMLSP Overage, L.P. | 0.4% | ||||
| FHMLSP Overage, L.L.C. | 0.4% | ||||
| Frazier Life Sciences X, L.P. | 0% | ||||
| FHMLS X, L.P. | 0% | ||||
| FHMLS X, L.L.C. | 0% | ||||
| Frazier Life Sciences XI, L.P. | 0% | ||||
| FHMLS XI, L.P. | 0% | ||||
| FHMLS XI, L.L.C. | 0% | ||||
| James N. Topper | 2.0% | ||||
| Patrick J. Heron | 2.0% | ||||
| Albert Cha | 1.9% | ||||
| James Brush | 1.9% | ||||
| Daniel Estes | 0% | ||||
|
Trevi Therapeutics, Inc.
13G/A
Amendment 3
TRVI · 89532M101
|
11.9% |
2/14/2025
Event 12/31/2024
|
|||
| Frazier Life Sciences Public Fund, L.P. | 9.9% | ||||
| FHMLSP, L.P. | 9.9% | ||||
| FHMLSP, L.L.C. | 9.9% | ||||
| Frazier Life Sciences X, L.P. | 0.5% | ||||
| FHMLS X, L.P. | 0.5% | ||||
| FHMLS X, L.L.C. | 0.5% | ||||
| Frazier Life Sciences XI, L.P. | 1.6% | ||||
| FHMLS XI, L.P. | 1.6% | ||||
| FHMLS XI, L.L.C. | 1.6% | ||||
| James N. Topper | 11.9% | ||||
| Patrick J. Heron | 11.9% | ||||
| Albert Cha | 9.9% | ||||
| James Brush | 9.9% | ||||
| Daniel Estes | 1.6% | ||||
|
Puma Biotechnology, Inc.
13G/A
Amendment 1
PBYI · 74587V107
|
0% |
2/14/2025
Event 12/31/2024
|
|||
| Frazier Life Sciences Public Fund, L.P. | 0% | ||||
| FHMLSP, L.P. | 0% | ||||
| FHMLSP, L.L.C. | 0% | ||||
| Frazier Life Sciences X, L.P. | 0% | ||||
| FHMLS X, L.P. | 0% | ||||
| FHMLS X, L.L.C. | 0% | ||||
| Frazier Life Sciences XI, L.P. | 0% | ||||
| FHMLS XI, L.P. | 0% | ||||
| FHMLS XI, L.L.C. | 0% | ||||
| James N. Topper | 0% | ||||
| Patrick J. Heron | 0% | ||||
| Albert Cha | 0% | ||||
| James Brush | 0% | ||||
| Daniel Estes | 0% | ||||
|
AN2 Therapeutics, Inc.
13G/A
Amendment 1
ANTX · 037326105
|
0% |
2/14/2025
Event 12/31/2024
|
|||
| Frazier Life Sciences Public Fund, L.P. | 0% | ||||
| FHMLSP, L.P. | 0% | ||||
| FHMLSP, L.L.C. | 0% | ||||
| Frazier Life Sciences X, L.P. | 0% | ||||
| FHMLS X, L.P. | 0% | ||||
| FHMLS X, L.L.C. | 0% | ||||
| Frazier Life Sciences XI, L.P. | 0% | ||||
| FHMLS XI, L.P. | 0% | ||||
| FHMLS XI, L.L.C. | 0% | ||||
| James N. Topper | 0% | ||||
| Patrick J. Heron | 0% | ||||
| Albert Cha | 0% | ||||
| James Brush | 0% | ||||
| Daniel Estes | 0% | ||||
|
Maze Therapeutics, Inc.
13G
MAZE · 578784100
|
7.3% |
2/10/2025
Event 2/3/2025
|
|||
| Frazier Life Sciences Public Fund, L.P. | 5.4% | ||||
| FHMLSP, L.P. | 5.4% | ||||
| FHMLSP, L.L.C. | 5.4% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.6% | ||||
| FHMLSP Overage, L.P. | 1.6% | ||||
| FHMLSP Overage, L.L.C. | 1.6% | ||||
| Frazier Life Sciences X, L.P. | 0.1% | ||||
| FHMLS X, L.P. | 0.1% | ||||
| FHMLS X, L.L.C. | 0.1% | ||||
| Frazier Life Sciences XI, L.P. | 0.2% | ||||
| FHMLS XI, L.P. | 0.2% | ||||
| FHMLS XI, L.L.C. | 0.2% | ||||
| James N. Topper | 7.3% | ||||
| Patrick J. Heron | 7.3% | ||||
| Albert Cha | 7.0% | ||||
| James Brush | 7.0% | ||||
| Daniel Estes | 0.2% | ||||
|
Palvella Therapeutics, Inc.
13G
PVLA · 697947109
|
5.1% |
1/8/2025
Event 12/13/2024
|
|||
| Frazier Life Sciences Public Fund, L.P. | 3.9% | ||||
| FHMLSP, L.P. | 3.9% | ||||
| FHMLSP, L.L.C. | 3.9% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.2% | ||||
| FHMLSP Overage, L.P. | 1.2% | ||||
| FHMLSP Overage, L.L.C. | 1.2% | ||||
| Frazier Life Sciences X, L.P. | 0% | ||||
| FHMLS X, L.P. | 0% | ||||
| FHMLS X, L.L.C. | 0% | ||||
| Frazier Life Sciences XI, L.P. | 0% | ||||
| FHMLS XI, L.P. | 0% | ||||
| FHMLS XI, L.L.C. | 0% | ||||
| James N. Topper | 5.1% | ||||
| Patrick J. Heron | 5.1% | ||||
| Albert Cha | 5.1% | ||||
| James Brush | 5.1% | ||||
| Daniel Estes | 0% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.